Investigators have reported, at the American Society for Therapeutic Radiation and Oncology (ASTRO) 50th Annual Meeting, that when radiation is added to anti-androgen therapy (ADT), survival rates are increased by 50% in men receiving only ADT. "This randomized trial is the first to show that men with locally advanced prostate cancer will survive substantially longer [...]
HIFU is becoming increasing popular as a primary alternative treatment for men diagnosed with prostate cancer that is confined in the gland. Commonly used in Europe and in Mexico, HIFU is also being evaluated in a clinical trials in the United States. As with all primary prostate cancer treatments, it too has a failure rate. [...]
April 14 in the Journal of Clinical Oncology reported that Eric M. Horwitz, M.D., from Fox Chase Cancer Center in Philadelphia, and colleagues treated 1,554 prostate cancer patients with goserelin and flutamide (ADT) before and during radiation therapy. The men were then randomly assigned to receive no further ADT or 24 additional months of ADT. [...]
